SHARED COMMITMENT TO A COMPLEX SCIENCE.
Curing pediatric cancer is such a big and complex challenge, it’s unrealistic to think that any one pediatric center can get the job done alone. By working together in a coordinated way, we can accomplish more, with greater benefits, at lower costs.
As a member, your institution will be able to participate in the CureWorks pipeline and provide innovative immunotherapies directly to your patients. This allows you to treat more patients locally, while redefining the standard of care globally. Members benefit from access to an array of technologies, data, and expertise, including clinical trial coordination and manufacturing of individual treatments.
Learn more about our science and progress.
Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing FeasibilityClinical Cancer Research
Clinical Cancer Research
Neuroblastoma is the most common extracranial solid tumor of childhood with a heterogeneous clinical course. While neuroblastomas with favorable biology spontaneously regress or differentiate without therapeutic intervention, neuroblastomas with unfavorable biology often fatally progress despite intensive multimodal therapy.
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
The New England Journal of Medicine
Glioblastoma, an aggressive primary brain tumor, is among the most lethal of human cancers. We present evidence of the potential therapeutic benefit of adoptive T-cell therapy against glioblastoma with the use of CAR-engineered T cells targeting IL13Rα2, a glioma-associated antigen linked to a reduced rate of survival.
Designing chimeric antigen receptors to effectively and safely target tumors
Clinical Cancer Research
The adoptive transfer of T cells engineered to express artificial chimeric antigen receptors CARs) that target a tumor cell surface molecule has emerged as an exciting new approach for cancer immunotherapy. Clinical trials in patients with advanced B cell malignancies treated with CD19-specific CAR-modified T cells (CAR-T) have shown impressive antitumor efficacy, leading to optimism that this approach will be useful for treating common solid tumors.
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Pub Med Central
CD19-specific chimeric antigen receptor (CAR)–expressing autologous T cells administered after lymphodepleting chemotherapy can induce clinical remissions in B-lineage malignancies, including refractory pediatric acute lymphoblastic leukemia (ALL), irrespective of disease burden or anatomic dissemination.